Further functional studies are needed to confirm the significance of our data indicating the involvement of the dysregulated expression of both BTLA and CTLA-4 checkpoint inhibitors in PB lymphocytes in CLL immunopathology. Here, BTLA is linked to B-cell chronic lymphocytic leukemia.